<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381990</url>
  </required_header>
  <id_info>
    <org_study_id>URN-13-1010</org_study_id>
    <nct_id>NCT02381990</nct_id>
  </id_info>
  <brief_title>MRI/Ultrasound Fusion Guided Prostate Cryotherapy</brief_title>
  <acronym>FIPC</acronym>
  <official_title>Office Based MRI/Ultrasound Guided Prostate Cryotherapy: Outcomes Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urological Research Network, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urological Research Network, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by&#xD;
      Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome&#xD;
      measure is 5 year oncological control. Secondary aim is lack of progression beyond the&#xD;
      prostate gland. The aim of intervention is to eradicate prostate cancer disease in the&#xD;
      treated area while imposing no or minimal deleterious effects in quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CLINICAL TRIAL OF OBSERVATION NATURE&#xD;
&#xD;
      PRIMARY OUTCOME&#xD;
&#xD;
      Cancer control of treated areas 5, 10, 15 years after intervention based on prostate biopsy&#xD;
      of initial treated area, progression requiring conversion to radical prostate surgery or&#xD;
      radiation or other forms of whole gland treatment (ej, HIFU), Metastatic Free survival: CT&#xD;
      Scan and Bone Scans, Cancer-Specific and Overall Survival&#xD;
&#xD;
      SECONDARY OUTCOMES&#xD;
&#xD;
      Secondary Interventions focal interventions due to de-novo lesions. Focal or target therapy&#xD;
      rescue with other technologies (ej HIFU); Short, Intermediate and Long-Term Urinary and&#xD;
      Sexual Function changes in quality of life measured by validated inventories; Anxiety related&#xD;
      to cancer and cancer control. Treatment tolerance to local anesthesia. Patient App compliance&#xD;
      and activity to monitor care&#xD;
&#xD;
      DATA COLLECTION&#xD;
&#xD;
        -  Complete H&amp;P, family history, past medical and surgical history, social history,&#xD;
           allergies, and medications&#xD;
&#xD;
        -  As of July 2016, voluntary measurement thru Focalyx App for smartphones and tablets&#xD;
&#xD;
        -  Imaging Specifics Assessing Prostate, Seminal Vesicles and Urethral Contouring by&#xD;
           Multi-parametric-MRI. Dominant lesions and secondary lesions contouring my MP-MRI.&#xD;
&#xD;
        -  Procedure specific Co-Registration quality with ultrasound denoting quality&#xD;
&#xD;
        -  Specific ablative description and digitalization of critical measures such as: ablation&#xD;
           type (ej cryotherapy, equipment used) procedure, cryoprobes used, freeze/thaw cycles&#xD;
           timing, temperatures at neurovascular bundles, denonvilliers fascia. Urethral warmer&#xD;
           requirements&#xD;
&#xD;
        -  Follow up information: 30 day perioperative outcomes (incidence of UTI, urinary&#xD;
           retention, failure of local anesthetic, pain measures). 6 week, 3,6,9,12 month and then&#xD;
           every 6 month measures of PSA, Testosterone levels, Urinary Function and Sexual Function&#xD;
           inventories, Overall anxiety and regret related to diagnosis and treatment&#xD;
&#xD;
        -  Uroflow and PVR measurements by 3 to 6 month of treatment&#xD;
&#xD;
        -  MP MRI on a yearly basis, for years 2,3,4 after treatment, biopsy driven by new&#xD;
           suspicious MRI findings&#xD;
&#xD;
        -  MP MRI triggered by elevation in PSA velocity or PSA level 10% above diagnosis&#xD;
&#xD;
        -  Transperineal Fusion Guided Prostate biopsy at 1st year - emphasis on treated areas,&#xD;
           suspicious MRI areas&#xD;
&#xD;
        -  Transperineal Fusion Guided Prostate biopsy at 5th year - emphasis on treated areas,&#xD;
           suspicious MRI areas&#xD;
&#xD;
        -  5, 10, 15 Yr CT Scans, PET Scan/Bone Scan&#xD;
&#xD;
      SAFETY MEASURES&#xD;
&#xD;
        -  Periodic evaluation of registry to ensure consistency in follow up&#xD;
&#xD;
        -  Patient remainders of tests required&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Anticipated">June 2035</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Oncological Control</measure>
    <time_frame>1 Year</time_frame>
    <description>Lack of prostate cancer presence in treated area after MRI/US FUSION Biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oncological Control</measure>
    <time_frame>1 Year</time_frame>
    <description>Lack of prostate cancer presence in the gland after MRI/US FUSION Biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological Control</measure>
    <time_frame>Yearly, up to 10 years</time_frame>
    <description>Lack of prostate cancer presence in gland measured by MP-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Functional Outcomes</measure>
    <time_frame>Every 3 months up to 24 months</time_frame>
    <description>Evaluation of urinary function outcomes when compared to baseline using expanded prostate composite index and AUA symptoms scores. Urinary function also by objective measurements - uroflow and post void residuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes</measure>
    <time_frame>30 days</time_frame>
    <description>Procedure tolerance, need for hospital admission or ER consultation, incidence of urinary tract infection, urinary retention, any significant side effect that may occur and perioperative survivel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Functional Outcomes</measure>
    <time_frame>Every 3 months up to 24 months</time_frame>
    <description>Evaluation of sexual function outcomes when compared to baseline using Sexual Inventory for men questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary Treatment Requirement</measure>
    <time_frame>Yearly, up to 10 years</time_frame>
    <description>Type of treatments required after initial intervention over time</description>
  </other_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Neoplasms Prostate</condition>
  <condition>Cancer of the Prostate</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY</intervention_name>
    <description>Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic &quot;cryoprobes/devices&quot; are employed to freeze and all &quot;circuled or noted&quot; cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins</description>
    <other_name>Intervention of Interest: Prostate Cryoablation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        As written in Initial Section&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men between 55 and 65 years of age with a clinical diagnosis of prostate cancer with&#xD;
             Low or Intermediate risk prostate cancer, and &lt;50% positive core rate by prostate lobe&#xD;
&#xD;
          -  Men older than 65 years of age with clinical diagnosis of prostate cancer &lt;50%&#xD;
             positive core rate by prostate lobe&#xD;
&#xD;
          -  Absence of extra-capsular extension&#xD;
&#xD;
          -  Absence of seminal vesicle invasion&#xD;
&#xD;
          -  Absence of regional or distant metastatic disease&#xD;
&#xD;
          -  Multiparametric MRI of the prostate performed either before the biopsy or &gt;10 weeks&#xD;
             after prostate biopsy&#xD;
&#xD;
          -  Treated with Cryotherapy of the prostate&#xD;
&#xD;
          -  Treatment based on co-registration between MP-MRI and Prostate Ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment of prostate cancer in the form of surgery.&#xD;
&#xD;
          -  Performance status greater than 0 based on ECOG criteria&#xD;
&#xD;
          -  Mental status impairment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FERNANDO J BIANCO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UROLOGICAL RESEARCH NETWORK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EUSEBIO LUNA, MD</last_name>
    <role>Study Director</role>
    <affiliation>UROLOGICAL RESEARCH NETWORK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel H Lopez, MD</last_name>
    <role>Study Director</role>
    <affiliation>UROLOGICAL RESEARCH NETWORK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CIELO D GUERRA, BS</last_name>
    <phone>305-515-9887</phone>
    <email>CIELO@BESTUROLOGY.NET</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LUANDA SIANO, PA</last_name>
    <phone>305-822-7227</phone>
    <email>LUANDA@BESTUROLOGY.NET</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urological Research Network</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CIELO D GUERRA, BS</last_name>
      <phone>305-515-9887</phone>
      <email>CIELO@BESTUROLOGY.NET</email>
    </contact>
    <investigator>
      <last_name>FERNANDO J BIANCO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>EDWARD L GHEILER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ARIEL M KAUFMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EUSEBIO J LUNA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct;64(4):544-52. doi: 10.1016/j.eururo.2013.03.030. Epub 2013 Mar 20.</citation>
    <PMID>23537686</PMID>
  </results_reference>
  <results_reference>
    <citation>Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21.</citation>
    <PMID>22445223</PMID>
  </results_reference>
  <results_reference>
    <citation>Costa DN, Pedrosa I, Donato F Jr, Roehrborn CG, Rofsky NM. MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. Radiographics. 2015 May-Jun;35(3):696-708. doi: 10.1148/rg.2015140058. Epub 2015 Mar 18. Review.</citation>
    <PMID>25786055</PMID>
  </results_reference>
  <results_reference>
    <citation>Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ; European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol. 2012 Apr;22(4):746-57. doi: 10.1007/s00330-011-2377-y. Epub 2012 Feb 10.</citation>
    <PMID>22322308</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.</citation>
    <PMID>25626035</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>PSA</keyword>
  <keyword>FUSION</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>MRI</keyword>
  <keyword>Cancer</keyword>
  <keyword>Cryotherapy</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Recurrence</keyword>
  <keyword>QOL, Quality of Life</keyword>
  <keyword>Urinary function</keyword>
  <keyword>Sexual Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Non identifiable pertinent information will be shared for other scientists to evaluate other pertinent questions</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

